Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014

News provided by

Jun 03, 2014, 09:49 ET

NEW YORK, June 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02133108/Mixed-Dyslipidemia-Global-Clinical-Trials-Review-H1-2014.html

Summary

GlobalData's clinical trial report, "Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014" provides data on the Mixed Dyslipidemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mixed Dyslipidemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mixed Dyslipidemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Mixed Dyslipidemia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Mixed Dyslipidemia to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Mixed Dyslipidemia to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Mixed Dyslipidemia 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Mixed Dyslipidemia Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Mixed Dyslipidemia 33
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 33
Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol 35
Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol 37
Mar 07, 2013: Kowa Pharma And Lilly Announce Results Of Study Evaluating Efficacy Of Livalo In HIV-infected Adults With Dyslipidemia 39
Dec 20, 2012: Merck Announces HPS2-THRIVE Study Of Tredaptive Does Not Achieve Primary Endpoint 40
Clinical Trial Profiles 41
Clinical Trial Overview of Top Companies 41
Novartis AG 41
Clinical Trial Overview of Novartis AG 41
Merck & Co., Inc. 43
Clinical Trial Overview of Merck & Co., Inc. 43
Abbott Laboratories 44
Clinical Trial Overview of Abbott Laboratories 44
AbbVie Inc. 45
Clinical Trial Overview of AbbVie Inc. 45
Amgen Inc. 46
Clinical Trial Overview of Amgen Inc. 46
Pfizer Inc. 47
Clinical Trial Overview of Pfizer Inc. 47
Kowa Company, Ltd. 48
Clinical Trial Overview of Kowa Company, Ltd. 48
AstraZeneca PLC 49
Clinical Trial Overview of AstraZeneca PLC 49
Daiichi Sankyo Company, Limited 50
Clinical Trial Overview of Daiichi Sankyo Company, Limited 50
CymaBay Therapeutics, Inc. 51
Clinical Trial Overview of CymaBay Therapeutics, Inc. 51
Clinical Trial Overview of Top Institutes / Government 52
Ministry of Education, Culture, Sports, Science and Technology 52
Clinical Trial Overview of Ministry of Education, Culture, Sports, Science and Technology 52
Sri Ramachandra Medical College & Research Institute 53
Clinical Trial Overview of Sri Ramachandra Medical College & Research Institute 53
Medical University of Silesia 54
Clinical Trial Overview of Medical University of Silesia 54
University of Pennsylvania 55
Clinical Trial Overview of University of Pennsylvania 55
Five Key Clinical Profiles 56
Appendix 121
Abbreviations 121
Definitions 121
Research Methodology 122
Secondary Research 122
About GlobalData 123
Contact Us 123
Disclaimer 123
Source 123

List of Tables
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mixed Dyslipidemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Mixed Dyslipidemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Mixed Dyslipidemia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Mixed Dyslipidemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Mixed Dyslipidemia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Mixed Dyslipidemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mixed Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mixed Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mixed Dyslipidemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mixed Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mixed Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mixed Dyslipidemia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Mixed Dyslipidemia Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mixed Dyslipidemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 41
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 43
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 44
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 45
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 46
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 47
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Kowa Company, Ltd., 2014* 48
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 49
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 50
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by CymaBay Therapeutics, Inc., 2014* 51
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ministry of Education, Culture, Sports, Science and Technology, 2014* 52
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sri Ramachandra Medical College & Research Institute, 2014* 53
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Silesia, 2014* 54
Mixed Dyslipidemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 55

List of Figures
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mixed Dyslipidemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Mixed Dyslipidemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Mixed Dyslipidemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Mixed Dyslipidemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Mixed Dyslipidemia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Mixed Dyslipidemia to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mixed Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mixed Dyslipidemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mixed Dyslipidemia to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mixed Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mixed Dyslipidemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Mixed Dyslipidemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Mixed Dyslipidemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Mixed Dyslipidemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 122